French biotech is bucking the chilled markets. Indeed, counting this week's announcement of a E35 million ($30.8 million) pre-IPO financing by neurological play Neurotech, five French biotech deals account for 26% of European company fundraising so far this year. In contrast, from 1996 through 2000, France accounted for only 6.5% of European fundraising (see "The French Share").